Acute lymphoblastic leukemia (ALL) treatment is evolving at a rapid pace and many HCPs may only see a few patients with B-cell precursor ALL per year. Spark ALL™ brings stakeholders together to advance the treatment landscape as we strive to provide the highest level of care for patients.

This resource is designed to leverage the experience of the Spark ALL™ committee, who have extensive clinical experience and are continuing to research the latest advancements in ALL treatment.

Continue to visit this website:

Find out more about treating ALL and continue the dialogue!


Understanding measurable residual disease (MRD)

why mrd matters why mrd matters

Why MRD matters

where to test for mrd where to test for mrd

Where to test for MRD

patient case studies patient case studies

View patient case studies

Hear from your peers

The prognostic value of MRD

jae park jae park
Jae Park

Associate Attending Physician
at Memorial Sloan Kettering Cancer Center

MRD testing methods

aaron logan aaron logan
Aaron Logan

Associate Professor of Clinical Medicine
at the University of California San Francisco

The importance of the first bone marrow aspirate pull

aaron logan aaron logan
Aaron Logan

Associate Professor of Clinical Medicine
at the University of California San Francisco

When to test for MRD

james mccloskey james mccloskey
James McCloskey

Interim Chief, Division of Leukemia
at the John Theurer Cancer Center

Presenters have been compensated for participating in this program.

Back to top